Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma

REFERENCES

1. 1.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Van Meir EG,
   3. Hadjipanayis CG,
   4. Norden AD, et al

   . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166–93

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Louis DN,
   3. Ohgaki H,
   4. Wiestler OD, et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Arvinda HR,
   3. Kesavadas C,
   4. Sarma PS, et al

   . Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 2009;94:87–96

   CrossRefPubMed
5. 5.↵
   2. Law M,
   3. Yang S,
   4. Wang H, et al

   . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

   Abstract/FREE Full Text
6. 6.↵
   2. Alexiou GA,
   3. Zikou A,
   4. Tsiouris S, et al

   . Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma. Clin Neurol Neurosurg 2014;116:41–45

   CrossRefPubMed
7. 7.↵
   2. Yoon JH,
   3. Kim JH,
   4. Kang WJ, et al

   . Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy. Eur Radiol 2014;24:380–89

   CrossRefPubMed
8. 8.↵
   2. Weber MA,
   3. Henze M,
   4. Tüttenberg J, et al

   . Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol 2010;45:755–68

   CrossRefPubMed
9. 9.↵
   2. Hu LS,
   3. Eschbacher JM,
   4. Dueck AC, et al

   . Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012;33:69–76

   Abstract/FREE Full Text
10. 10.↵
    2. LaViolette PS,
    3. Cohen AD,
    4. Prah MA, et al

    . Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol 2013;15:442–50

    Abstract/FREE Full Text
11. 11.↵
    2. Mangla R,
    3. Ginat DT,
    4. Kamalian S, et al

    . Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 2014;116:325–31

    CrossRefPubMed
12. 12.↵
    2. Law M,
    3. Young RJ,
    4. Babb JS, et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Wang DJ,
    3. Alger JR,
    4. Qiao J, et al

    . The value of arterial spin-labeled perfusion imaging in acute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced MRI. Stroke 2012;43:1018–24

    Abstract/FREE Full Text
14. 14.↵
    2. Wang DJ,
    3. Alger JR,
    4. Qiao J, et al

    . Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke—comparison with dynamic susceptibility contrast enhanced perfusion imaging. Neuroimage Clin 2013;3:1–7

    CrossRefPubMed
15. 15.↵
    2. Warmuth C,
    3. Gunther M,
    4. Zimmer C

    . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Noguchi T,
    3. Yoshiura T,
    4. Hiwatashi A, et al

    . Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density. AJNR Am J Neuroradiol 2008;29:688–93

    Abstract/FREE Full Text
17. 17.↵
    2. Chawla S,
    3. Wang S,
    4. Wolf RL, et al

    . Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683–89

    Abstract/FREE Full Text
18. 18.↵
    2. Kim HS,
    3. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99

    Abstract/FREE Full Text
19. 19.↵
    2. Tykocinski ES,
    3. Grant RA,
    4. Kapoor GS, et al

    . Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012;14:613–23

    Abstract/FREE Full Text
20. 20.↵
    2. Zhan Y,
    3. O'Rourke DM

    . SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res 2004;64:8292–98

    Abstract/FREE Full Text
21. 21.↵
    2. Gan HK,
    3. Kaye AH,
    4. Luwor RB

    . The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748–54

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Feldkamp MM,
    3. Lala P,
    4. Lau N, et al

    . Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:1442–53

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Pelloski CE,
    3. Ballman KV,
    4. Furth AF, et al

    . Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288–94

    Abstract/FREE Full Text
24. 24.↵
    2. Nagane M,
    3. Levitzki A,
    4. Gazit A, et al

    . Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998;95:5724–29

    Abstract/FREE Full Text
25. 25.↵
    2. Mellinghoff IK,
    3. Wang MY,
    4. Vivanco I, et al

    . Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–24

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Raizer JJ

    . HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 2005;74:77–86

    CrossRefPubMed
27. 27.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72

    Abstract/FREE Full Text
28. 28.↵
    2. Louis DN,
    3. Holland EC,
    4. Cairncross JG

    . Glioma classification: a molecular reappraisal. Am J Pathol 2001;159:779–86

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Yoshimoto K,
    3. Dang J,
    4. Zhu S, et al

    . Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008;14:488–93

    Abstract/FREE Full Text
30. 30.↵
    2. Wang J,
    3. Alsop DC,
    4. Song HK, et al

    . Arterial transit time imaging with flow encoding arterial spin tagging (FEAST). Magn Reson Med 2003;50:599–607

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Schmainda KM,
    3. Prah M,
    4. Connelly J, et al

    . Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 2014;16:880–88

    Abstract/FREE Full Text
32. 32.↵
    2. Essock-Burns E,
    3. Lupo JM,
    4. Cha S, et al

    . Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:119–31

    Abstract/FREE Full Text
33. 33.↵
    2. Piccioni DE,
    3. Lai A

    . Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol 2014;16:1427–28

    FREE Full Text
34. 34.↵
    2. Alsop DC,
    3. Detre JA,
    4. Golay X, et al

    . Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2014 Apr 8. [Epub ahead of print]